Bovine, Canine, Equine, Gallus, Human, Mouse, Rabbit, Rat
Immunogen:
KLH conjugated synthetic peptide derived from human MAP3K8
Conjugation:
Unconjugated
Alternative Names:
augmented in rheumatoid arthritis 2,AURA2,Cancer Osaka thyroid oncogene,c-COT,COT,cot (cancer Osaka thyroid) oncogene,EST,ESTF,Ewing sarcoma transformant,MEKK8,mitogen-activated protein kinase kinase kinase 8,proto-oncogene c-Cot,proto-oncogene serine/threoine protein kinase,Serine/threonine-protein kinase cot,Tpl-2,TPL2,tumor progression locus 2.
Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.
